Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Owusu Agyei, Seth ^a,b   Ansong, Daniel ^c   Asante, Kwaku ^a   Owusu, Sandra Kwarteng ^c   Owusu, Ruth ^a   Brobby, Naana Ayiwa Wireko ^c   Dosoo, David ^a   Akoto, Alex Osei ^c   Osei Kwakye, Kingsley ^a   Adjei, Emmanuel Asafo ^c   Boahen, Kwadwo Owusu ^a   Sylverken, Justice ^c   Adjei, George ^a   Sambian, David ^c   Apanga, Stephen ^a   Kayan, Kingsley ^a   Vekemans, Johan ^d   Ofori Anyinam, Opokua ^d   Leach, Amanda ^d   Lievens, Marc ^d   Demoitie, Marie Ange ^d   Dubois, Marie Claude ^d   Cohen, Joe ^d   Ballou, W Ripley ^e   Savarese, Barbara ^f   Chandramohan, Daniel ^b   Gyapong, John Owusu ^g   Milligan, Paul ^b   Antwi, Sampson ^c   Agbenyega, Tsiri ^c   Greenwood, Brian ^b   Evans, Jennifer ^h   more..

^a Health Research Unit Ghana Health Service   (Ghana)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f PATH Malaria Vaccine Initiative   (United States)

^g MINISTRY OF HEALTH   (Ghana)

^h KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIBIOTIC AGENT; ARTESUNATE; AS01E VACCINE; AS02D VACCINE; HEPATITIS B SURFACE ANTIBODY; MALARIA VACCINE; PARACETAMOL; QUININE; RABIES VACCINE; RTS S VACCINE; UNCLASSIFIED DRUG; RTS,S AS01E VACCINE; RTS,S AS02D VACCINE; RTS,S-AS01E VACCINE; RTS,S-AS02D VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; BLOODY DIARRHEA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; FEBRILE CONVULSION; FEMALE; FEVER; GHANA; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALARIA; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SIDE EFFECT; VOMITING; ANIMAL; CHILD; DRUG ADMINISTRATION; IMMUNOLOGY; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; TIME; TREATMENT OUTCOME; VACCINATION;

HEPATITIS B VIRUS;

ANIMALS; AREA UNDER CURVE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GHANA; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 70350002150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007302     Document Type: Article

References (24)

1. Breman JG, Egan A, Keusch GT (2001) Introduction and Summary. The intolerable burden of malaria: a new look at the numbers. American Journal of Tropical Medicine and Hygiene 64 (1, 2) S: iv-vii.
2. Sachs JD (2002) A new global effort to control malaria. Science 298(5591): 122-4.
3. Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, et al. (2006) Preclinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24(42-43): 6483-6492.
4. Kester KE (2005) Malaria-027 trial results. WRAIR sponsored satellite presentation at ASTMH Philadelphia USA 11-15th December 2005.
5. Polhemus ME (2006) MAL 044 phase IIb clinical trial comparing two GSK adjuvant formulations AS01B and AS02A at the Walter Reed Project, Kisumu, Kenya. WRAIR sponsored satellite presentation at ASTMH Atlanta GA USA 13-16th November 2006.
6. Alonso PL, Sacarlal J, Aponte JJ, Leach L, Macete E, et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366: 2012-18.
7. Macete EV, Sacarlal J, Aponte JJ, Leach A, Navia MM, et al. (2007) Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. Trials 8: 11.
8. Lell B (2007) A randomized, observer-blind trial to compare safety and immunogenicity of two adjuvanted RTS,S anti-malaria vaccine candidates in Gabonese children. Presented at ASTMH Philadelphia USA November 5-7th 2007.
9. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. NEJM 359: 2533-44.
10. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. NEJM 359: 2521-32.
11. Bonhoeffer J, Menkes J, Gold M, de Souza-Brito G, Fisher M, et al. (2004) The Brighton Collaboration Seizure Working Group. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22: 557-562.
12. WHO/IVR (2005) State of the art of vaccine research and development: Initiative for vaccine research World Health Organization, January 2005. .
13. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomized trial. The Lancet 358: 1927-34.
14. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2007) RTS,S malaria vaccine evaluation group. a phase IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine 25: 5359-66.
15. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, et al. (1999) A phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SABAS2, in semi-immune adults in The Gambia. Am J Trop Med Hyg 61: 865-868.
16. Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, et al. (2006) Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of Western Kenya. Am J Trop Med Hyg 75: 166-70.
17. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 364: 1411-1420.
18. Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat Q, et al. (2008) Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26: 174-184.
19. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366: 2012-18.
20. Bojang K, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, et al. (2005) Phase I safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23 (32): 4148-57.
21. Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, et al. (2007) Safety, reactogenicity and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1 to 4 years in Mozambique. Trop Med Int Health 12(1): 37-46.
22. Archampong EQ, Naaeder SB, Darko R. Changing pattern of intestinal obstruction in Accra, Ghana. Hepatogastroenterology 2000; 47: 185-193.
23. Hadler SC, de Monzon MA, Lugo DR, Perez M (1989) Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 7(2): 106-10.
24. Jilg W, Schmidt M, Deinhardt F (1989) Four-year experience with a recombinant vaccine. Infection 17: 70-6.